<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Future Shlock &#187; consumer patients</title>
	<atom:link href="http://www.dannybelkin.com/tag/consumer-patients/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.dannybelkin.com</link>
	<description>Futurism, Technology, Parenthood, and whatever else is on my mind at the moment.</description>
	<lastBuildDate>Sun, 15 Aug 2010 22:24:45 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=abc</generator>
		<item>
		<title>Trends in pharma &#8211; connecting marketing and product development</title>
		<link>http://www.dannybelkin.com/2009/12/further-trends-in-pharma-marketing-development/</link>
		<comments>http://www.dannybelkin.com/2009/12/further-trends-in-pharma-marketing-development/#comments</comments>
		<pubDate>Thu, 10 Dec 2009 21:43:41 +0000</pubDate>
		<dc:creator>Danny</dc:creator>
				<category><![CDATA[Business]]></category>
		<category><![CDATA[Innovations]]></category>
		<category><![CDATA[Medicine]]></category>
		<category><![CDATA[consumer patients]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[product development]]></category>

		<guid isPermaLink="false">http://www.dannybelkin.com/?p=481</guid>
		<description><![CDATA[One of the major disconnects in the pharma industry, for a variety of reasons (historical, regulatory, organizational) is  the one between product development and the marketing which follows. Products have always been developed mostly tailored to functional specs, with the needs and convenience of patients who end up taking the medicines a secondary, or marginal, [...]]]></description>
		<wfw:commentRss>http://www.dannybelkin.com/2009/12/further-trends-in-pharma-marketing-development/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
